Dual Inhibitors of Hepatitis C Virus and Hepatocellular Carcinoma: Design, Synthesis and Docking Studies

Overview

Journal Future Sci OA

Specialty Biotechnology

Date 2017 Dec 20

PMID 29255624

Citations 1

Authors

Mostafa Mm El-Miligy

Samia M Rida

Fawzia A Ashour

Mona H Badr

Ehab M El-Bassiony

Maha A El-Demellawy

Ashraf M Omar

Affiliations

Soon will be listed here.

Abstract

Aim: Simultaneous inhibition of hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) may enhance anti-HCV effects and reduce resistance and side effects.

Results/methodology: Novel hybrid derivatives were designed and synthesized to exhibit dual activity against HCV and its associated major complication, HCC. The synthesized compounds were screened for their potential activity against HCV and HCC. Compounds and exhibited potential anticancer activity against HCC cell line HepG2, while compounds and showed anti-HCV activity. Docking studies suggested that the newly synthesized compounds could suppress HCC through VEGFR2 tyrosine kinase inhibition.

Conclusion: Compounds and exhibited dual activity against HCV and HCC .

Citing Articles

The Role of AMP-Activated Protein Kinase as a Potential Target of Treatment of Hepatocellular Carcinoma.

Jiang X, Tan H, Teng S, Chan Y, Wang D, Wang N Cancers (Basel). 2019; 11(5).

PMID: 31083406 PMC: 6562911. DOI: 10.3390/cancers11050647.

References

Huynh H . Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010; 80(5):550-60. DOI: 10.1016/j.bcp.2010.03.034. View

Liang G, Liu Z, Wu J, Cai Y, Li X . Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci. 2012; 33(10):531-41. DOI: 10.1016/j.tips.2012.07.001. View

Gale Jr M, Kwieciszewski B, Dossett M, Nakao H, Katze M . Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol. 1999; 73(8):6506-16. PMC: 112733. DOI: 10.1128/JVI.73.8.6506-6516.1999. View

Kaushik-Basu N, Bopda-Waffo A, Talele T, Basu A, Chen Y, Kucukguzel S . 4-Thiazolidinones: a novel class of hepatitis C virus NS5B polymerase inhibitors. Front Biosci. 2008; 13():3857-68. DOI: 10.2741/2974. View

Flint T, HIRSCHBERG E, Murray M . Comparative effects of chemotherapeutic agents on Brown-Pearce tumor and normal rabbit testis in vitro. Proc Soc Exp Biol Med. 1953; 84(2):493-6. DOI: 10.3181/00379727-84-20689. View

Gawande S, Warangkar S, Bandgar B, Khobragade C . Synthesis of new heterocyclic hybrids based on pyrazole and thiazolidinone scaffolds as potent inhibitors of tyrosinase. Bioorg Med Chem. 2013; 21(10):2772-7. DOI: 10.1016/j.bmc.2012.12.053. View

Stanaway J, Flaxman A, Naghavi M, Fitzmaurice C, Vos T, Abubakar I . The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016; 388(10049):1081-1088. PMC: 5100695. DOI: 10.1016/S0140-6736(16)30579-7. View

Omar K, Geronikaki A, Zoumpoulakis P, Camoutsis C, Sokovic M, Ciric A . Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs. Bioorg Med Chem. 2009; 18(1):426-32. DOI: 10.1016/j.bmc.2009.10.041. View

deLemos A, Chung R . Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med. 2014; 20(6):315-21. DOI: 10.1016/j.molmed.2014.02.002. View

10.

Aerts M, Benteyn D, Van Vlierberghe H, Thielemans K, Reynaert H . Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol. 2016; 22(1):253-61. PMC: 4698490. DOI: 10.3748/wjg.v22.i1.253. View

11.

Kanda T, Yokosuka O, Omata M . Hepatitis C virus and hepatocellular carcinoma. Biology (Basel). 2014; 2(1):304-16. PMC: 4009856. DOI: 10.3390/biology2010304. View

12.

Sangro B, Inarrairaegui M, Bilbao J . Radioembolization for hepatocellular carcinoma. J Hepatol. 2011; 56(2):464-73. DOI: 10.1016/j.jhep.2011.07.012. View

13.

Estfan B, Byrne M, Kim R . Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2012; 36(4):319-24. DOI: 10.1097/COC.0b013e3182468039. View

14.

Bernard M, Hulley E, Molenda H, STOCHLA K, Wrzeciono U . [Azoles. 17. Beta-(4-pyrazol)acrylic and propionic acids and their anti-inflammatory activity]. Pharmazie. 1986; 41(8):560-2. View

15.

Boyum A . Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968; 97:77-89. View

16.

Kammasud N, Boonyarat C, Tsunoda S, Sakurai H, Saiki I, Grierson D . Novel inhibitor for fibroblast growth factor receptor tyrosine kinase. Bioorg Med Chem Lett. 2007; 17(17):4812-8. DOI: 10.1016/j.bmcl.2007.06.058. View

17.

Thaher B, Arnsmann M, Totzke F, Ehlert J, Kubbutat M, Schachtele C . Tri- and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases. J Med Chem. 2011; 55(2):961-5. DOI: 10.1021/jm201391u. View

18.

Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten T . Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology. 2012; 84(1):6-13. DOI: 10.1159/000342425. View

19.

Prasath R, Bhavana P, Ng S, Tiekink E . 3-(4-Meth-oxy-phen-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde. Acta Crystallogr Sect E Struct Rep Online. 2012; 67(Pt 11):o2962-3. PMC: 3247369. DOI: 10.1107/S1600536811041808. View

20.

Vicini P, Geronikaki A, Incerti M, Zani F, Dearden J, Hewitt M . 2-Heteroarylimino-5-benzylidene-4-thiazolidinones analogues of 2-thiazolylimino-5-benzylidene-4-thiazolidinones with antimicrobial activity: synthesis and structure-activity relationship. Bioorg Med Chem. 2008; 16(7):3714-24. DOI: 10.1016/j.bmc.2008.02.001. View